News Related News

Lord David Prior of Brampton to Keynote SynBioBeta London

We are proud to have Lord David Prior of Brampton as a keynote speaker for SynBioBeta London 2017. Lord Prior was recently appointed Parliamentary Under Secretary of State at the Department for Business, Energy and Industrial Strategy in December 2016, [...]

By | March 14th, 2017|News|

The Tools, Challenges, and Future Uses for Renewable Bio-based Materials

In synthetic biology, the term biodesign describes the many layers of the process by which new bio-based products are innovated. Not only does this process involve the design and engineering of microbes to generate valuable raw materials, but also molding [...]

By | March 14th, 2017|News|

Neal Carter

Neal Carter is the president and founder of Okanagan Specialty Fruits Inc. (OSF), a dynamic agriculture biotechnology company specializing in the creation of novel tree fruit varieties. OSF’s flagship project, nonbrowning Arctic® apple varieties, recently became the first genetically engineered [...]

By | March 14th, 2017|News|

Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases

DUBLIN, Ireland and CAMBRIDGE, Mass., March 14, 2017 (GLOBE NEWSWIRE) -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and [...]

By | March 14th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|

CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyte

BASEL, Switzerland, CAMBRIDGE, Mass., and GAITHERSBURG, Md., March 14, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer AG [...]

By | March 14th, 2017|News, Press Releases|

Intrexon Creates Precigen, Inc. and Accelerates Strategic Review of Structural Options Related to Health Assets

GERMANTOWN, Md., March 10, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the formation of Precigen, Inc., a wholly-owned [...]

By | March 14th, 2017|BioPharma & Healthcare, News, Press Releases, Therapeutics|